Lakefront Biotherapeutics (LKFT) Non-cash Items (2016 - 2017)
Lakefront Biotherapeutics (LKFT) posted quarterly Non-cash Items of -$34.8 billion for Q2 2017, down 779737.71% year-on-year from N/an in Q2 2016, and down 324955.03% on a QoQ basis from -$10.7 million in Q1 2017.
Lakefront Biotherapeutics (LKFT) Non-cash Items (2016 - 2017) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Non-cash Items for 2 consecutive years, with -$34.8 billion the latest figure, recorded in Q2 2017.
- Quarterly Non-cash Items fell 779737.71% year-over-year to -$34.8 billion in Q2 2017, while the trailing twelve-month figure through Jun 2017 was -$34.8 billion (changed N/A YoY) and the FY2016 annual result came in at $7.5 million, up 106.37% from the prior year.
- Non-cash Items fell to -$34.8 billion in Q2 2017 per LKFT's latest filing, from -$10.7 million in the prior quarter.
- Over the last five years, Non-cash Items for LKFT reached as high as -$4.5 million in Q2 2016 and fell as low as -$34.8 billion in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Lakefront Biotherapeutics | 1.85 Bn | -1.64 Bn | 1.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | -34.80 Bn |
| Jun 30, 2017 | -34.80 Bn |
| Mar 31, 2017 | -10.71 Mn |
| Mar 31, 2017 | -10.71 Mn |
| Jun 30, 2016 | -4.46 Mn |
| Jun 30, 2016 | -4.46 Mn |
| Mar 31, 2016 | -21.95 Mn |
| Mar 31, 2016 | -21.95 Mn |